Comparing Opdivo vs Pembrolizumab
| Opdivo (nivolumab) | Pembrolizumab |
|
|---|
| Opdivo (nivolumab) | Pembrolizumab |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Opdivo is an immune checkpoint inhibitor that may be used to treat many different cancers including melanoma, bladder cancer, liver cancer, colorectal cancer, and lung cancer. Fatigue, skin... View more |
Prescription only
Prescribed for Bladder Cancer, Breast Cancer, Biliary Tract Tumor, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Carcinoma, Gastric Cancer, Head and Neck Cancer, Hepatocellular... View more |
Related suggestions Colorectal Cancer
Popular comparisons
|
|||||||
| More about Opdivo (nivolumab) | More about Pembrolizumab | ||||||||
| Ratings & Reviews | |||||||||
|
Opdivo has an average rating of 5.9 out of 10 from a total of 97 ratings on Drugs.com. 54% of reviewers reported a positive effect, while 39% reported a negative effect. |
Pembrolizumab has an average rating of 5.3 out of 10 from a total of 292 ratings on Drugs.com. 44% of reviewers reported a positive effect, while 43% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
View all Opdivo side effects |
View all Pembrolizumab side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
N/A |
N/A |
||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
View all Opdivo prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | |||||||||
|
N/A |
||||||||
| Brand Names | |||||||||
|
N/A |
Keytruda | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
640.8 hours |
624 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 605 drugs are known to interact with Opdivo:
|
A total of 605 drugs are known to interact with Pembrolizumab:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
December 22, 2014 |
N/A |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
|
|||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.